BioAtla, Inc. (BCAB)
| Market Cap | 1.53B |
| Revenue (ttm) | 7.77M |
| Net Income (ttm) | -20.76M |
| Shares Out | 32.09M |
| EPS (ttm) | -0.65 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 15 |
| Last Price | $45.38 |
| Previous Close | $46.52 |
| Change ($) | -1.14 |
| Change (%) | -2.45% |
| Day's Open | 46.76 |
| Day's Range | 44.97 - 48.15 |
| Day's Volume | 120,714 |
| 52-Week Range | 31.02 - 48.15 |
SAN DIEGO, Jan. 8, 2021 /PRNewswire/ -- BioAtla, Inc., a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics, to...
Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason — they believe the stock price will rise and they want to profit from it. So insider bu...
SAN DIEGO, Dec. 18, 2020 /PRNewswire/ -- BioAtla, Inc. (Nasdaq: BCAB), a clinical-stage biopharmaceutical company developing a novel class of highly specific and selective antibody-based thera...
SAN DIEGO, Dec. 15, 2020 /PRNewswire/ -- BioAtla, Inc. (Nasdaq: BCAB), a clinical-stage biopharmaceutical company developing a novel class of highly specific and selective antibody-based thera...
San Diego, California-based BioAtla was founded to develop conditionally active biologics that 'exploit characteristic pH differences between the tumor microenvironment and healthy tissue.'
BioAtla, a Phase 2 biotech developing antibody therapies for solid tumor cancers, filed on Friday with the SEC to raise up to $100 million in an initial public offering.
BioAtla, Inc. has filed to go public with an IPO on the New York Stock Exchange (NYSE).
About BCAB
BioAtla, a biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of various cancers. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and other tumor types. It also develops BA3021, a CAB ADC for NSCLC and Melanoma; and BA3071, which is a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for renal cell carcinoma, NSCLC, small cell lung cancer, hepatoc... [Read more...]
| Industry Biotechnology | IPO Date Dec 16, 2020 |
| CEO Jay M. Short | Employees 35 |
| Stock Exchange NASDAQ | Ticker Symbol BCAB |
Financial Performance
In 2019, BioAtla's revenue was $5.20 million, a decrease of -51.07% compared to the previous year's $10.63 million. Losses were -$29.79 million, 2.81% more than in 2018.
Analyst Forecasts
According to 4 analysts, the average rating for BioAtla stock is "Buy." The 12-month stock price forecast is 50.00, which is an increase of 10.18% from the latest price.